Mithra Issues a Put Option Notice Under Capital Agreement with LDA Capital

Liege, Belgium, 13 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the issuance of a put option notice, according to the terms of the capital commitment agreement signed with LDA Capital Limited on April 24, 2020. Under the terms of this agreement extended in April […]

Presentation of Donesta® Phase 3 Topline Efficacy Results at the 20th ISGE World Congress

Liege, Belgium, 12 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that several presentations focusing on therapeutic opportunities for estetrol (E4) will be held at the 20th World Congress of the International Society of Gynecological Endocrinology (ISGE) taking place from 11-14 May 2022 in Florence, Italy. […]

Publication of a Transparency Notification Received from Glenernie Capital

Liege, Belgium, 06 May 2022 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), […]

Publication of Transparency Notifications Received from Goldman Sachs

Liege, Belgium, 29 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that […]

Mithra CDMO Announces Collaboration with MedinCell for the Development of Injectable Products for Malaria and Transplant Rejection

Liege, Belgium, 26 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA) today announces a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège. Mithra CDMO offers a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal […]

Information on the Total Number of Voting Rights (denominator) following Exercise of a Call Option from Goldman Sachs

Liege, Belgium, 20 April 2022 – 07:30 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that Goldman Sachs International (“GSI”) has elected to exercise a call option for an amount of EUR 5,000,000 on 19 April, 2022, according to the terms of the […]

Mithra Releases Invitation to its General Ordinary and Extraordinary Securities holders’ Meeting

Liege, Belgium, 19 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the invitation to its ordinary and extraordinary securities holders’ meeting that will be held on Thursday May 19 2022 at 2:00 PM (CEST). The notice for the General Meeting including a description of the […]

Mithra Announces the Extension of the Capital Commitment Agreement with LDA Capital by Two Years and the Increase of the Commitment by EUR 25 million

Liege, Belgium, 18 April 2022 – 7:30 CEST – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (“Mithra” or the “Company”), a company dedicated to Women’s Health, today announces the extension of the capital commitment agreement with LDA Capital Limited (“LDA Capital“) for a period of two additional years, as well as the increase of the commitment […]

Mithra Releases 2021 Annual Report

Liege, Belgium, 15 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2021 Annual Report. The Annual Report which outlines Mithra’s achievements in 2021 includes the following information: – Overview of Mithra’s R&D pipeline and letter to shareholders; – Highlights of Mithra’s […]

Mithra Announces Improved Consolidated Topline Results from Donesta® Phase 3 Studies and Launch of Recruitment for the Extension of European Study

• Consolidated analysis of Phase 3 topline data showed even more positive results than initially announced, with all four co-primary endpoints met • Donesta® safety profile confirmed by independent Data Safety Monitoring Board (DSMB), which recommended to continue the Phase III Clinical Program • Launch of the recruitment of the additional 300 menopausal women thanks […]